Perrigo Company plc or ImmunityBio, Inc.: Who Invests More in Innovation?

Innovation Investment: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals and biotechnology, innovation is the lifeblood of progress. Over the past decade, Perrigo Company plc and ImmunityBio, Inc. have demonstrated contrasting approaches to research and development (R&D) investments.

Perrigo Company plc: Steady Commitment

Perrigo has consistently allocated a significant portion of its resources to R&D, with expenses peaking in 2018. Despite a slight decline in recent years, Perrigo's investment remains robust, averaging around 16% higher than ImmunityBio's over the period.

ImmunityBio, Inc.: Rapid Growth

In contrast, ImmunityBio has shown a remarkable upward trend, with R&D expenses increasing by over 14,000% from 2014 to 2023. This surge underscores ImmunityBio's aggressive pursuit of innovation, particularly in the last five years.

Conclusion

While Perrigo maintains a steady course, ImmunityBio's rapid growth in R&D spending highlights its commitment to pioneering advancements in biotechnology.